Mga Batayang Estadistika
| CIK | 879682 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Viveve Medical, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-11388 Commission File Number VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-233639 Form S-1 Regis |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-233639 Form S-1 Regis |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-233639 Form S-1 Regis |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. S-8 POS 1 vive20230125es8pos.htm FORM S-8 POS As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI |
|
| January 27, 2023 |
Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 RW 1 vive20230125rw.htm FORM RW Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 January 26, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Viveve Medical, Inc. Registration Statement on Form S-1 (File No. 333-268311) Ladies and Gentlemen: Pursua |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-233639 Form S-1 Regis |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-257648 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-3 Registration No. 333-257648 UNDER THE SECURITIES ACT OF 1933 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 04-3153858 (State or other jurisdict |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-233639 Form S-1 Regis |
|
| January 27, 2023 |
As filed with the Securities and Exchange Commission on January 26, 2023. POS AM 1 vive20230125dposam.htm FORM POS AM As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S- |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 17, 2023 |
Exhibit 99.1 Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence Study's primary efficacy endpoint was not achieved at 12 months post-treatment Company has implemented a reduction in force Company will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD, CO – January 17, 2023 – Viveve Medical, Inc. (NASDAQ: VIVE), a me |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2023 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 15, 2022 |
Exhibit 99.1 Viveve Announces Completion of Pivotal U.S. PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded Topline results of the 12-month primary efficacy endpoint anticipated in January 2023 Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urinary incontinence in women ENGLEWOOD, CO – |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 6, 2022 |
As filed with the Securities and Exchange Commission on December 6, 2022 As filed with the Securities and Exchange Commission on December 6, 2022 Registration No. |
|
| December 2, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 1, 2022 |
Exhibit 99.1 Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trial ENGLEWOOD, CO – December 1, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's h |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 23, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 14, 2022 |
Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 November 14, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Viveve Medical, Inc. Registration Statement on Form S-1 (File No. 333-268311) Ladies and Gentlemen: Reference is made to the registration |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE M |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Viveve Medical, Inc. |
|
| November 10, 2022 |
Exhibit 99.1 Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tips PURSUIT clinical trial completion expected by year-end Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO – November 10, 2022 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company fo |
|
| November 10, 2022 |
Power of Attorney^ (included on signature page hereto) As filed with the Securities and Exchange Commission on November 10, 2022 Registration No. |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| October 4, 2022 |
Exhibit 99.1 Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence Patent issuance further strengthens Viveve?s intellectual property portfolio for the treatment of female stress urinary incontinence ENGLEWOOD, CO ? October 4, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and the treat |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission F |
|
| September 27, 2022 |
Exhibit 99.1 Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout New branding reflects Company?s vision to be the leader in the treatment of Stress Urinary Incontinence in Women Completion of PURSUIT follow-up visits anticipated by the end of 2022 with topline results expected shortly therea |
|
| September 26, 2022 |
Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 September 26, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: Viveve Medical, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-257648, Filed July 2, |
|
| September 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Viveve Medical, Inc. |
|
| September 23, 2022 |
As filed with the Securities and Exchange Commission on September 23, 2022. As filed with the Securities and Exchange Commission on September 23, 2022. Registration No. 333-257648 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 04-3153858 (State or other jurisdiction of incorporatio |
|
| September 22, 2022 |
Viveve to Participate in Ladenburg Thalmann Healthcare Conference Exhibit 99.1 Viveve to Participate in Ladenburg Thalmann Healthcare Conference ENGLEWOOD, CO ? September 22, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, September |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission F |
|
| September 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission F |
|
| September 15, 2022 |
Viveve to Participate in Alliance Global Partners Virtual MedTech Conference Exhibit 99.1 Viveve to Participate in Alliance Global Partners Virtual MedTech Conference ENGLEWOOD, CO ? September 15, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Alliance Global Partners Virtual MedTech |
|
| September 1, 2022 |
Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference Exhibit 99.1 Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference ENGLEWOOD, CO ? September 1, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 24th Annual Global In |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 11, 2022 |
Exhibit 99.1 Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tips PURSUIT clinical trial follow-up visit completion anticipated by year end Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO ? August 11, 2022 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical tec |
|
| August 11, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDICA |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 12, 2022 |
Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan Exhibit 99.1 Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan Englewood, CO ? July 12, 2022 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women?s health and the treatment of stress urinary incontinence (SUI), today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. I766557 for Viveve?s dual-energ |
|
| June 3, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 31, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 17, 2022 |
Viveve to Participate in H.C. Wainwright Global Investment Conference Exhibit 99.1 Viveve to Participate in H.C. Wainwright Global Investment Conference ENGLEWOOD, CO ? May 17, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright Global Investment Conference, May 23 - 26, 2022. Mr. Durbin will deliver the Viveve corporate |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 12, 2022 |
Exhibit 99.1 Viveve Reports First Quarter 2022 Financial Results and Provides Corporate Update Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO ? May 12, 2022 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focu |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDIC |
|
| May 12, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 12, 2022 |
Fifth Amended and Restated Viveve Medical, Inc. Independent Director Compensation Policy. Exhibit 10.1 FIFTH AMENDED AND RESTATED VIVEVE MEDICAL, INC. INDEPENDENT DIRECTOR COMPENSATION POLICY The Board of Directors (the ?Board?) of Viveve Medical, Inc. (the ?Company?) has adopted the following amended and restated compensation policy (this ?Policy?), effective as of April 12, 2022 (the ?Effective Date?) for directors of the Company who are not employees of the Company or any parent or |
|
| May 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 17, 2022 |
Exhibit 99.1 Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treatment follow-up visits underway PURSUIT top-line results anticipated at end of 2022 Conference call to be ho |
|
| March 17, 2022 |
Certificate of Elimination of Series C Preferred Stock(40) Exhibit 3.9 CERTIFICATE OF ELIMINATION OF SERIES C CONVERTIBLE PREFERRED STOCK, A SERIES OF PREFERRED STOCK OF VIVEVE MEDICAL, INC. (Pursuant to Section 151(g) of the Delaware General Corporation Law) VIVEVE MEDICAL, INC., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), does hereby certify that the following resolutions respecting Series C Converti |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from . |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 17, 2022 |
Exhibit 4.20 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021 Viveve Medical, Inc. (?Viveve?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): common stock, par value $0.0001 per share (the ?common stock?). DESCRIPTION OF COMMON |
|
| March 17, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| February 4, 2022 |
VIVE / Viveve Medical Inc / Hudson Bay Capital Management LP - VIVE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92852W501 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 21, 2022 |
Form of Retention Bonus Agreement (39) Exhibit 10.1 January , 2022 BY EMAIL [NAME] Re: Retention Bonus Opportunity Dear : At this time, the Company considers it to be in the best interests of Viveve Medical, Inc. (the ?Company?) to promote and preserve the employment of certain employees (the ?Specified Employees?). You are a Specified Employee and, therefore, the Company?s has determined that appropriate steps should be taken to reinf |
|
| January 18, 2022 |
VIVE / Viveve Medical Inc / Empery Asset Management, LP - VIVEVE MEDICAL, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 92852W501 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 5, 2022 |
As filed with the Securities and Exchange Commission on January 4, 2022 As filed with the Securities and Exchange Commission on January 4, 2022 Registration No. |
|
| December 14, 2021 |
Exhibit 99.1 Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence Major milestone achieved in Company?s advance toward a new U.S. SUI indication ENGLEWOOD, CO ? December 14, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, announced today that it has completed enrollment in its pivot |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 12, 2021 |
Exhibit 99.1 Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update Total revenue of $1.6M reported for Q3 Pivotal SUI PURSUIT trial enrollment nears completion ? randomizations on-track for completion in Q4 ENGLEWOOD, CO ? November 11, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial re |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE M |
|
| November 12, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 28, 2021 |
Exhibit 99.1 Viveve Announces Issuance of New Device and Methods Patent in U.S. Issuance further expands and strengthens Company?s intellectual property portfolio Englewood, CO ? October 28, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Pate |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 23, 2021 |
Exhibit 99.1 Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence ENGLEWOOD, CO ? September 23, 2021 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the Australian |
|
| September 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission F |
|
| September 7, 2021 |
Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference Exhibit 99.1 Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference ENGLEWOOD, CO ? September 7, 2021 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 ? 15, 2021. |
|
| September 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDICA |
|
| August 12, 2021 |
Exhibit 99.1 Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update Total revenue of $1.7M reported for Q2 Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarter Pivotal SUI PURSUIT trial enrollment on-track for completion in early Q4 Potential long-term reimbursement pathway established with new Category III CPT? code |
|
| August 12, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| August 3, 2021 |
Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent Exhibit 99.1 Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent Englewood, CO ? August 3, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women?s intimate health, today announced that the Canadian Intellectual Property Office (CIPO) recently issued Canadian Patent No. 3028905 for Viveve?s dual-energy technology device and metho |
|
| July 7, 2021 |
Exhibit 99.1 Viveve Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure New code approved by American Medical Association and supported by key medical societies Long-term pathway for potential reimbursement now established for Company?s dual-energy noninvasive treatment for urethral hypermobility to improve stress urinary incontinence in women Englewood, CO ? July 7, |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| July 6, 2021 |
Viveve to Participate in Ladenburg Thalmann Healthcare Virtual Conference Exhibit 99.1 Viveve to Participate in Ladenburg Thalmann Healthcare Virtual Conference ENGLEWOOD, CO ? July 6, 2021 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, July 13 - 14, 2021. Mr. Durbin will deliver the Viveve |
|
| July 2, 2021 |
As filed with the Securities and Exchange Commission on July 2, 2021 Registration No. |
|
| July 2, 2021 |
Power of Attorney (included on the signature pages to this registration statement) S-3 1 vive20210630s3.htm As filed with the Securities and Exchange Commission on July 2, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 04-3153858 (State or other jurisdiction of incorporation or o |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 16, 2021 |
Amendment to the Amended and Restated Bylaws. Exhibit 3.1 AMENDMENT TO AMENDED AND RESTATED BYLAWS OF VIVEVE MEDICAL, INC. The Amended and Restated Bylaws (the ?Bylaws?) of Viveve Medical, Inc., a Delaware corporation (the ?Company?) were amended by a resolution adopted by the board of directors of the Company on June 15, 2021 as follows: The first sentence of Article I, Section 5 of the Bylaws is hereby deleted in its entirety and replaced w |
|
| June 16, 2021 |
DEFA14A 1 vive20210615defa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the Appropriate Box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| June 16, 2021 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 10, 2021 |
EX-99.1 2 ex256474.htm EXHIBIT 99.1 Exhibit 99.1 Viveve Announces Issuance of New Device and Methods Patent in U.S. Issuance expands patent claims for Company’s dual-energy technology Englewood, CO – June 10, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recentl |
|
| June 2, 2021 |
EX-99.1 2 ex254314.htm EXHIBIT 99.1 Exhibit 99.1 VIVEVE ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern Time - Company encourages stockholders to cast their votes ENGLEWOOD, CO – June 2, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 202 |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 2, 2021 |
Press Release issued by the Company on June 2, 2021, furnished herewith. EX-99.1 2 ex254314.htm EXHIBIT 99.1 Exhibit 99.1 VIVEVE ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern Time - Company encourages stockholders to cast their votes ENGLEWOOD, CO – June 2, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 202 |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 13, 2021 |
Results of Operations and Financial Condition 8-K 1 vive202105138k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of |
|
| May 13, 2021 |
Exhibit 99.1 Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update Pivotal SUI PURSUIT trial enrollment underway and accelerating Total revenue of $1.5M for Q1 including sale of 2,450 consumable treatment tips Strengthened patent portfolio in key Asia Pacific markets ENGLEWOOD, CO ? May 13, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDIC |
|
| May 11, 2021 |
Press Release issued by the Company on May 11, 2021, furnished herewith. Exhibit 99.1 VIVEVE ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene June 2, 2021 at 12:00 PM Eastern Time - Company encourages stockholders to cast their votes ENGLEWOOD, CO ? May 11, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2021 Annual Meeting of Stockholders due |
|
| May 11, 2021 |
Exhibit 99.1 VIVEVE ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene June 2, 2021 at 12:00 PM Eastern Time - Company encourages stockholders to cast their votes ENGLEWOOD, CO ? May 11, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2021 Annual Meeting of Stockholders due |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 20, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-254926 3,500,000 Shares Common Stock This prospectus relates to the offer and sale of up to 3,500,000 shares of common stock, par value $0.0001 per share, of Viveve Medical, Inc., a Delaware corporation, by Lincoln Park Capital Fund, LLC, or Lincoln Park or the Selling Stockholder. The shares of common stock being offered by the Selling Stockho |
|
| April 15, 2021 |
Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, CO 80112 Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, CO 80112 VIA EDGAR April 15, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tom Jones Tim Buchmiller Re: Viveve Medical, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333- 254926 Dear Messrs. Jones and |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 1, 2021 |
Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan EX-99.1 2 ex238656.htm EXHIBIT 99.1 Exhibit 99.1 Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan Englewood, CO – April 1, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. 1720358 for Viveve’s dual-energy technolo |
|
| March 31, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| March 31, 2021 |
As filed with the Securities and Exchange Commission on March 31, 2021 Registration No. |
|
| March 31, 2021 |
Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on March 31, 2021 Registration No. |
|
| March 31, 2021 |
DEF 14A 1 vive20210329def14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted |
|
| March 31, 2021 |
EX-10.1 2 ex238431.htm EXHIBIT 10.1 Exhibit 10.1 FIRST AMENDMENT TO PURCHASE AGREEMENT THIS FIRST AMENDMENT TO PURCHASE AGREEMENT (this “First Amendment”), dated as of March 31, 2021, by and between VIVEVE MEDICAL, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS, the Company and the Investor entered i |
|
| March 18, 2021 |
Exhibit 10.27 FIRST AMENDMENT TO SUBLEASE AGREEMENT THIS FIRST AMENDMENT TO SUBLEASE AGREEMENT (hereinafter referred to as this ?Amendment?) is made effective as of March 15, 2021 (the ?Effective Date?) by and between Ingredion Incorporated, a Delaware corporation (?Sublandord?), and Viveve Medical, Inc., a Delaware corporation (?Subtenant?). WITNESSETH: WHEREAS, Sublandord and Subtenant are party |
|
| March 18, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| March 18, 2021 |
Exhibit 4.20 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020 Viveve Medical, Inc. (?Viveve?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): common stock, par value $0.0001 per share (the ?common stock?). DESCRIPTION OF COMMON |
|
| March 18, 2021 |
Exhibit 99.1 Viveve Reports Full Year 2020 Financial Results and Provides Corporate Update Company continuing to advance its U.S. pivotal PURSUIT trial in stress urinary incontinence Conference call to be hosted by Company at 5:00 PM ET today Englewood, CO – March 18, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financi |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from . |
|
| February 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 18, 2021 |
Exhibit 99.1 Viveve Announces Preliminary Topline Financial Results for Fourth Quarter 2020 - Q4 revenue growth, reduced operating expenses and successful closing of public offering in January position Company with capital resources through end of 2022 - Company to host year-end conference call on March 18, 2021 at 5:00 PM ET Englewood, CO – February 18, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92852W501 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 2, 2021 |
Viveve Announces Expansion of IP Portfolio with Issuance of S. Korean Patent EX-99.1 2 ex223738.htm EXHIBIT 99.1 Exhibit 99.1 Viveve Announces Expansion of IP Portfolio with Issuance of S. Korean Patent Englewood, CO – February 2, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the Korean Intellectual Property Office (KIPO) recently issued Korean Patent No. 10-2197234 titled, Vaginal Remodeli |
|
| February 2, 2021 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 21, 2021 |
Exhibit 99.1 Viveve Announces Initiation of Pivotal U.S. PURSUIT Trial in Stress Urinary Incontinence - New study design is more highly powered with improved patient selection criteria to better assess the primary efficacy endpoint - Positive results could support a marketing application for new U.S. stress urinary incontinence indication ENGLEWOOD, CO – January 21, 2021 – Viveve Medical, Inc. (NA |
|
| January 21, 2021 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 19, 2021 |
Exhibit 99.1 VIVEVE ANNOUNCES CLOSING OF AN UPSIZED $27.6 MILLION UNDERWRITTEN PUBLIC OFFERING AND EXERCISE OF OVER-ALLOTMENT OPTION ENGLEWOOD, CO / ACCESSWIRE / January 19, 2021 / Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced the closing of an upsized underwritten public offering of units for gross proceeds of appr |
|
| January 19, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 92852W501 (CUSIP Number) January 14, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 19, 2021 |
Exhibit 3.1 VIVEVE MEDICAL, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Scott Durbin and Heidi Mayon, do hereby certify that: 1. They are the Chief Executive Officer and Secretary, respectively, of Viveve Medical, Inc., a Delaware corporation (the “Cor |
|
| January 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VIVEVE MEDICAL, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 92852W303 (CUSIP Number) January 14, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 14, 2021 |
PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-251517 4,607,940 Class A Units consisting of 4,607,940 shares of common stock and warrants to purchase up to 4,607,940 shares of common stock and 2,450,880 Class B Units consisting of 2,450,880 shares of Series C Preferred Stock and warrants to purchase up to 2,450,880 shares of common stock (and 9,509,700 shares of common stock unde |
|
| January 13, 2021 |
January 13, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| January 13, 2021 |
As filed with the Securities and Exchange Commission on January 13, 2021 Registration No. |
|
| January 13, 2021 |
Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, CO 80112 VIA EDGAR January 13, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Alan Campbell Re: Viveve Medical, Inc. Acceleration Request for Registration Statement on Form S-1 Filed December 18, 2020 File |
|
| January 13, 2021 |
As filed with the Securities and Exchange Commission on January 13, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 3841 04-3153858 (State or other jurisdiction of (Primary Standard Industrial (I.R. |
|
| January 12, 2021 |
Form of Underwriting Agreement* Exhibit 1.1 UNDERWRITING AGREEMENT between VIVEVE MEDICAL, INC. and A.G.P./ALLIANCE GLOBAL PARTNERS, as Representative of the Several Underwriters Viveve Medical, Inc. UNDERWRITING AGREEMENT New York, New York January , 2021 A.G.P./Alliance Global Partners As Representative of the several Underwriters named on Schedule 1 attached hereto 590 Madison Avenue, 28th Floor New York, New York 10022 Ladie |
|
| January 12, 2021 |
Form of Common Stock Purchase Warrant for the 2021 Warrants (35) Exhibit 4.16 COMMON STOCK PURCHASE WARRANT VIVEVE medical, INC. Warrant Shares: Original Issue Date: , 2021 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise |
|
| January 12, 2021 |
As filed with the Securities and Exchange Commission on January 12, 2021 Registration No. |
|
| January 12, 2021 |
EX-4.18 4 ex220561.htm EXHIBIT 4.18 Exhibit 4.18 WARRANT AGENT AGREEMENT This Warrant Agent Agreement made as of [], 2021, is between Viveve Medical, Inc., a Delaware corporation, with offices at 345 Inverness Drive South, Building B, Suite 250, Englewood, CO 80112 (the “Company”), and VStock Transfer, LLC, with offices at 18 Lafayette Place, Woodmere, New York (the “Warrant Agent”). WHEREAS, the |
|
| January 4, 2021 | ||
| December 31, 2020 |
Form of Underwriting Agreement* Exhibit 1.1 UNDERWRITING AGREEMENT between VIVEVE MEDICAL, INC. and A.G.P./ALLIANCE GLOBAL PARTNERS, as Representative of the Several Underwriters Viveve Medical, Inc. UNDERWRITING AGREEMENT New York, New York , 2021 A.G.P./Alliance Global Partners As Representative of the several Underwriters named on Schedule 1 attached hereto 590 Madison Avenue, 28th Floor New York, New York 10022 Ladies and Ge |
|
| December 31, 2020 |
As filed with the Securities and Exchange Commission on December 31, 2020 Registration No. |
|
| December 31, 2020 |
Exhibit 3.8 VIVEVE MEDICAL, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, and , do hereby certify that: 1. They are the Chief Executive Officer and Secretary, respectively, of Viveve Medical, Inc., a Delaware corporation (the “Corporation”). 2. The Corpo |
|
| December 18, 2020 |
As filed with the Securities and Exchange Commission on December 18, 2020 Registration No. |
|
| December 17, 2020 |
Certificate of Elimination of Series A Preferred Stock (34) Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK, A SERIES OF PREFERRED STOCK OF VIVEVE MEDICAL, INC. (Pursuant to Section 151(g) of the Delaware General Corporation Law) VIVEVE MEDICAL, INC., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that the following resolutions respecting Series A Converti |
|
| December 17, 2020 |
Viveve Regains Compliance with NASDAQ Continued Listing Rules Exhibit 99.1 Viveve Regains Compliance with NASDAQ Continued Listing Rules ENGLEWOOD, CO – December 17, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on December 16, 2020 that the Company has regained compliance with the $1.00 minimum bid price requiremen |
|
| December 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 10, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 10, 2020 |
Exhibit 99.1 Viveve Announces FDA Approval of Proposed Amendments to Pivotal U.S. PURSUIT Trial Protocol - Viveve authorized to increase trial size and introduce new patient selection criteria designed to improve study?s power and data to support assessment of primary efficacy endpoint - Near-term launch planned for pivotal U.S. PURSUIT trial ENGLEWOOD, CO ? December 10, 2020 ? Viveve Medical, Inc |
|
| December 3, 2020 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 3, 2020 |
Viveve Announces FDA 510K Approval to Expand Manufacturing of Treatment Tips Exhibit 99.1 Viveve Announces FDA 510K Approval to Expand Manufacturing of Treatment Tips - Approval strengthens supply chain and reduces manufacturing costs for consumable component used with Viveve’s Cryogen-cooled Monopolar Radiofrequency technology ENGLEWOOD, CO – December 3, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today anno |
|
| December 1, 2020 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VIVEVE MEDICAL, INC. Viveve Medical, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: That the name of the Corporation is Viveve Medical, Inc. The date of the filing of its original Certificate of Incorporation w |
|
| December 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE M |
|
| November 12, 2020 |
Viveve Reports Third Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Viveve Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Company shifts strategic focus to stress urinary incontinence - Positive feasibility study and preclinical results advance clinical development program targeting treatment of stress urinary incontinence - Near-term launch planned for U.S. pivotal PURSUIT trial - Company to host conference call at 5:00 |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 10, 2020 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 10, 2020 |
Viveve to Participate in Alliance Group Partners Virtual Healthcare Symposium Exhibit 99.1 Viveve to Participate in Alliance Group Partners Virtual Healthcare Symposium ENGLEWOOD, CO – November 10, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the Alliance Group Partners Virtual Healthcare Symposium on November 19, 2020. Mr. Durbin w |
|
| October 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 30, 2020 |
Viveve Appoints New Independent Board Director Exhibit 99.1 Viveve Appoints New Independent Board Director ENGLEWOOD, CO – October 30, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that Sharon Collins Presnell, Ph.D. has joined the Viveve board of directors and its audit committee, effective October 28, 2020. The appointment of Dr. Presnell brings the company in com |
|
| October 27, 2020 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 27, 2020 |
Exhibit 99.1 Viveve Launches New Clinical Advisory Board in Urinary Incontinence Preeminent urology and urogynecology experts to help guide and advance the company’s pivotal U.S. PURSUIT trial in Stress Urinary Incontinence ENGLEWOOD, CO – October 27, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that it has formed a cl |
|
| September 22, 2020 |
Exhibit 99.1 Viveve Announces Issuance of Novel U.S. Method Patent for Stress Urinary Incontinence New patent strengthens and expands Viveve’s intellectual property portfolio for the treatment of stress urinary incontinence ENGLEWOOD, CO – September 22, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that the United State |
|
| September 22, 2020 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission F |
|
| September 3, 2020 |
Viveve to Present at H.C. Wainwright 22nd Annual Global Investment Conference Exhibit 99.1 Viveve to Present at H.C. Wainwright 22nd Annual Global Investment Conference ENGLEWOOD, CO – September 3, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference. Mr. Durbin will also meet with me |
|
| September 3, 2020 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 1, 2020 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 1, 2020 |
Viveve Announces Exercise of Warrants for $3.6 Million Exhibit 99.1 Viveve Announces Exercise of Warrants for $3.6 Million - Proceeds to support upcoming pivotal PURSUIT Trial in U.S. following recent announcement of positive results from SUI feasibility and preclinical studies ENGLEWOOD, CO – September 1, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced it has received $3.6 m |
|
| August 25, 2020 |
Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| August 25, 2020 |
Exhibit 99.1 Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company’s New Sham Tip for Pivotal PURSUIT Trial - Achievement of primary efficacy endpoint in 3-arm SUI feasibility study demonstrates significant separation between CMRF treatment arm and inert sham arm - Positive in-vivo preclinical study validates new i |
|
| August 13, 2020 |
Viveve Reports Second Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Viveve Reports Second Quarter 2020 Financial Results and Provides Corporate Update - Advanced critical SUI feasibility study for late summer readout - Achieved FDA clearance to conduct pivotal SUI PURSUIT Trial - Company to host conference call at 5:00 PM ET today ENGLEWOOD, CO – August 13, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's int |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDICA |
|
| August 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| July 23, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 14, 2020 |
Exhibit 99.1 Viveve Announces Clearance of Viveve 2.0 System in Thailand Regulatory clearance expands availability of next-generation CMRF system in key Southeast Asia market ENGLEWOOD, CO – July 14, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced it has received regulatory clearance from the Thai Food and Drug Administra |
|
| July 14, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 7, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| July 7, 2020 |
Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-239280 5,000,000 Shares Common Stock This prospectus relates to the offer and sale of up to 5,000,000 shares of common stock, par value $0.0001 per share, of Viveve Medical, Inc., a Delaware corporation, by Lincoln Park Capital Fund, LLC, or Lincoln Park or the Selling Stockholder. The shares of common stock being offered by the Selling Stockh |
|
| July 7, 2020 |
Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-239279 5,063,374 Shares Common Stock The selling stockholders named in this prospectus may offer and sell from time to time up to an aggregate of 5,063,374 shares of common stock issued or issuable upon exercise of warrants. We will not receive any proceeds from the sale by the selling stockholders of their shares of common stock other than th |
|
| July 7, 2020 |
Exhibit 99.1 Viveve Announces FDA Approval to Conduct PURSUIT Trial for Improvement of Stress Urinary Incontinence Initiation of pivotal PURSUIT trial is targeted for Q4 2020 following pending results from Company's SUI feasibility study, which is evaluating a new sham treatment tip PURSUIT clearance and pending results from the SUI feasibility study are significant milestones in Company's pursuit |
|
| July 1, 2020 |
Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, CO 80112 VIA EDGAR July 1, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tom Jones Tim Buchmiller Re: Viveve Medical, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-239280 Dear Messrs. Jones and Buc |
|
| July 1, 2020 |
Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, CO 80112 VIA EDGAR July 1, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tom Jones Tim Buchmiller Re: Viveve Medical, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-239279 Dear Messrs. Jones and Buc |
|
| June 30, 2020 |
Press Release issued on June 29, 2020 Exhibit 99.1 VIVEVE MEDICAL ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene July 22, 2020 at 10:30 AM Eastern Time ENGLEWOOD, CO – June 29, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2020 Annual Meeting of Stockholders in order to permit stockholders additional time |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 AMENDMENT NO. |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 30, 2020 |
VIVEVE MEDICAL ANNOUNCES ADJOURNMENT OF ANNUAL MEETING Exhibit 99.1 VIVEVE MEDICAL ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene July 22, 2020 at 10:30 AM Eastern Time ENGLEWOOD, CO – June 29, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2020 Annual Meeting of Stockholders in order to permit stockholders additional time |
|
| June 30, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 18, 2020 |
Goodwin Procter LLP 601 Marshall Street Redwood City, CA 94063 goodwinlaw.com +1 650 752 3100 June 18, 2020 Ms. Laura Crotty Ms. Mary Beth Breslin Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Viveve Medical, Inc. Registration Statement on Form S-3 Filed May 14, 2020 File No. 333-238263 Dear Misses Crotty an |
|
| June 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 AMENDMENT NO. |
|
| June 18, 2020 |
Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on June 18, 2020 Registration No. |
|
| June 18, 2020 |
Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on June 18, 2020 Registration No. |
|
| June 18, 2020 |
Goodwin Procter LLP 601 Marshall Street Redwood City, CA 94063 goodwinlaw.com +1 650 752 3100 June 18, 2020 Mr. David Burton Ms. Lynn Dicker Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Viveve Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed March 19, 2020 File No. 001-11388 Dear Mr |
|
| June 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 10, 2020 |
Purchase Agreement between the Registrant and Lincoln Park Capital, LLC dated June 8, 2020 (31) Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of June 8, 2020, by and between VIVEVE MEDICAL, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Inve |
|
| June 10, 2020 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 8, 2020, is entered into by and between VIVEVE MEDICAL, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined h |
|
| May 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| May 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDIC |
|
| May 14, 2020 |
Viveve Reports First Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Viveve Reports First Quarter 2020 Financial Results and Provides Corporate Update - First quarter continued to demonstrate success of the recurring revenue model - Organization focused on advancing stress urinary incontinence clinical strategy - Company to host conference call at 5:00 PM ET today ENGLEWOOD, CO – May 14, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology |
|
| May 14, 2020 |
As filed with the Securities and Exchange Commission on May 14, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 04-3153858 (State or other jurisdiction of incorporation or organization) (I.R.S. Empl |
|
| May 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 21, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| April 24, 2020 |
Exhibit 10.1 U.S. Small Business Administration NOTE SBA Loan # 96956271-08 SBA Loan Name Viveve, Inc. Date 04/23/2020 Loan Amount $1,343,400.00 Interest Rate 1.00% per annum Borrower Viveve, Inc., a Delaware Corporation Operating Company N/A Lender Western Alliance Bank, an Arizona Corporation 1. PROMISE TO PAY: In return for the Loan, Borrower promises to pay to the order of Lender the amount of |
|
| April 17, 2020 |
Form of Series A-2/B-2 Common Stock Purchase Warrant issued on April 20, 2020 (29) Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 17, 2020 |
Form of Inducement Letter (28) Exhibit 10.1 VIVEVE MEDICAL, INC. April , 2020 Holder of Common Stock Purchase Warrant Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Viveve Medical, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the Series A Common Stock Purchase Warrants and/or the Series B Common Stock Purchase Warrants of the Company set forth on the signature |
|
| April 17, 2020 |
EX-99.3 6 ex181765.htm EXHIBIT 99.3 Exhibit 99.3 Viveve Announces Update to Corporate Strategy Reconfirms plans for near-term focus on Stress Urinary Incontinence clinical strategy Announces plans to further reduce operating expenses and cash burn rate Strengthens balance sheet through warrant exercise for approximately $3 million in proceeds ENGLEWOOD, CO – April 17, 2020 – Viveve Medical, Inc. ( |
|
| April 17, 2020 |
Viveve Announces Exercise of Warrants for $3 Million Gross Proceeds Exhibit 99.2 Viveve Announces Exercise of Warrants for $3 Million Gross Proceeds ENGLEWOOD, CO - (Marketwired) – April 17, 2020 - Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that it has entered into agreements with several institutional and accredited investors to exercise certain outstanding Series A warrants to |
|
| April 17, 2020 |
Viveve Medical, Inc. 342 Inverness Drive South, Building B, Suite 250 Englewood, Colorado 80112 Exhibit 99.1 Viveve Medical, Inc. 342 Inverness Drive South, Building B, Suite 250 Englewood, Colorado 80112 April 15, 2020 VStock Transfer, LLC 18 Lafayette Place Woodmere, New York 11598 Attn: Young D. Kim, Esq. Re: Viveve Medical, Inc. Series A Warrants (CUSIP: 92852W 121) and Series B warrants (CUSIP: 92852W 113) Ladies and Gentlemen: Please be advised that, effective April 15, 2020, pursuant |
|
| April 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| April 17, 2020 |
Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-233639 PROSPECTUS SUPPLEMENT NO. 1 DATED APRIL 17, 2020 (To Prospectus dated November 22, 2019) VIVEVE MEDICAL, INC. 978,202 Class A Units consisting of shares of common stock and warrants to purchase up to 1,956,404 shares of common stock and 5,473,410 Class B Units consisting of shares of Series A Preferred Stock and warrants to purchase up |
|
| April 16, 2020 |
Exhibit 99.1 Viveve Announces Approval of Viveve 2.0 System in Canada Viveve 2.0 System now available throughout North America, Asia, and over 30 European countries ENGLEWOOD, CO – April 16, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced it has received regulatory clearance from the Canadian Ministry of Health for the Co |
|
| April 16, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| April 15, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| April 15, 2020 |
Exhibit 99.1 Viveve Resubmits U.S. Investigational Device Exemption to FDA to Conduct New PURSUIT Trial for Improvement of Stress Urinary Incontinence Proposed pivotal trial reinforces the company’s strategic pursuit of label expansion for Cryogen-cooled, Monopolar Radiofrequency (CMRF) technology in SUI indication ENGLEWOOD, CO – April 15, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical tec |
|
| April 9, 2020 |
Exhibit 99.1 Viveve Announces Topline Results from Pivotal U.S. VIVEVE II Trial for Improvement of Sexual Function in Women ENGLEWOOD, CO – April 9, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced topline results from the VIVEVE II clinical trial. VIVEVE II is a multicenter, randomized, double-blinded, sham-controlled stu |
|
| April 9, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 26, 2020 |
Viveve Announces Clearance of Next Generation 2.0 System in Taiwan Exhibit 99.1 Viveve Announces Clearance of Next Generation 2.0 System in Taiwan - Viveve 2.0 cryogen-cool monopolar radiofrequency technology and consumable treatment tips are now available in the U.S., China, Hong Kong, South Korea, Taiwan and more than 30 European countries ENGLEWOOD, CO – March 26, 2020 – Viveve Medical, Inc. (NASDAQ-VIVE), a medical technology company focused on women's intima |
|
| March 26, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| March 19, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| March 19, 2020 |
VIVE / Viveve Medical, Inc. S-8 - - FORM S-8 As filed with the Securities and Exchange Commission on March 19, 2020 Registration No. |
|
| March 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from . |
|
| March 19, 2020 |
Viveve Reports Full Year 2019 Financial Results Exhibit 99.1 Viveve Reports Full Year 2019 Financial Results - Company completes successful U.S. commercial transition from traditional capital sales model to recurring revenue rental model - Landmark pivotal sexual function trial (VIVEVE II) completed with data readout scheduled for April - SUI clinical development program with short-term feasibility study continues to advance - Company to host c |
|
| March 19, 2020 |
Description of Securities (31) Exhibit 4.17 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Viveve Medical, Inc. (“Viveve”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): common stock, par value $0.0001 per share (the “common stock”). DESCRIPTION OF COMMON STOCK The following summ |
|
| March 12, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File |
|
| March 12, 2020 |
Exhibit 99.1 Viveve Announces Completion of VIVEVE II Pivotal FDA Clinical Trial for Improvement of Sexual Function - Unblinded top-line results of the 12-month U.S. study anticipated in April - If positive, results may support a 2020 marketing application for an expanded U.S. indication for improvement of sexual function in women ENGLEWOOD, CO – March 12, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE |
|
| March 4, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 4, 2020 |
Viveve Completes Enrollment in Short-Term Feasibility Study for Stress Urinary Incontinence Exhibit 99.1 Viveve Completes Enrollment in Short-Term Feasibility Study for Stress Urinary Incontinence - Three-arm study compares Viveve’s Cryogen-cooled Monopolar Radiofrequency (CMRF) treatment and cryogen-only sham to inert sham treatment - Topline results anticipated in third quarter 2020 Englewood, CO – March 4, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focuse |
|
| February 14, 2020 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 14, 2020 |
VIVMF / Viveve Medical, Inc. / RTW INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. ) * Viveve Medical, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92852W303 (CUSIP Number) November 26, 2019 (Date of Even |
|
| February 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* VIVEVE MEDICAL INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92852W204 (CUSIP Number) June 30, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 11, 2020 |
VIVMF / Viveve Medical, Inc. / UBS Group AG - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viveve Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92852W303 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 10, 2020 |
VIVMF / Viveve Medical, Inc. / CVI Investments, Inc. - SC 13G/A Passive Investment CUSIP No: 92852W303 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Viveve Medical, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92852W303 (CUSIP Number |
|
| February 7, 2020 |
VIVMF / Viveve Medical, Inc. / Hudson Bay Capital Management LP - VIVE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92852W303 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 14, 2020 |
Viveve Initiates Enrollment of its Short-Term Feasibility Study in Stress Urinary Incontinence Exhibit 99.1 Viveve Initiates Enrollment of its Short-Term Feasibility Study in Stress Urinary Incontinence - Three-arm, three-month study will compare Viveve’s cryogen-cooled monopolar radiofrequency (CMRF) treatment and cryogen-only sham to inert sham treatment ENGLEWOOD, CO – January 14, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, |
|
| January 14, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 31, 2019 |
Viveve Announces Compliance with Nasdaq Listing Rules Exhibit 99.1 Viveve Announces Compliance with Nasdaq Listing Rules ENGLEWOOD, CO – December 31, 2019 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, announced today that it has been notified by Nasdaq that Viveve has regained compliance with the Nasdaq Capital Market continued listing requirements, the scheduled hearing before the Nasdaq Hear |
|
| December 31, 2019 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2019 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 18, 2019 |
Exhibit 99.1 Viveve Announces Authorization to Initiate Short-Term Feasibility Study in Stress Urinary Incontinence from Canadian Ministry of Health - Three-arm, three-month study will compare Viveve’s cryogen-cooled monopolar radiofrequency (CMRF) treatment and cryogen-only sham to an inert sham treatment ENGLEWOOD, CO – December 18, 2019 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technolog |
|
| December 18, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2019 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 10, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2019 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi |
